NCT06926933 - Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

April 20, 2026

Study Completion Date

October 30, 2027

Conditions

CPP

Interventions

DRUG

Eligard® 45 mg

45 mg of leuprolide acetate

Trial Locations (9)

RECRUITING

Korea University Ansan Hospital, Ansan

RECRUITING

Jeonbuk National University Hospital, Jeonju

RECRUITING

Chosun University Hospital, Kwangju

RECRUITING

Seoul National University Bundang Hospital, Seongnam

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Gangnam Severance Hospital, Seoul

RECRUITING

Kangdong Sacred Heart Hospital, Seoul

RECRUITING

Kyung Hee University Hospital At Gangdong, Seoul

RECRUITING

Ajou University Medical Center, Suwon